Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

C20H18N6Na2O7S4 drug entity composition and preparation for children

A technology of c20h18n6na2o7s4 and composition, applied in the pharmaceutical field, can solve the problems of leakage of water-soluble drugs, low encapsulation efficiency, difficulty in achieving encapsulation efficiency, etc.

Active Publication Date: 2017-12-01
广东金城金素制药有限公司
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with most liposome preparation methods, the encapsulation efficiency of water-soluble drug liposomes is significantly lower than that of fat-soluble drugs
Because the oil-water partition coefficient of water-soluble drugs is greatly affected by environmental factors, it is difficult to control the encapsulation; at the same time, in the process of encapsulation, water-soluble drugs are simultaneously distributed in the inner and outer water phases of liposomes, and the volume of the outer water phase is usually Larger than the internal water phase, it is difficult to achieve the ideal encapsulation efficiency after forming liposomes
In addition, after liposome encapsulation of water-soluble drugs, they will reconstitute in the outer water phase, inner water phase, and oil phase, resulting in leakage of water-soluble drugs
C 20 h 18 N 6 Na 2 o 7 S 4 Literature reports on making liposomes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • C20H18N6Na2O7S4 drug entity composition and preparation for children
  • C20H18N6Na2O7S4 drug entity composition and preparation for children
  • C20H18N6Na2O7S4 drug entity composition and preparation for children

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Weigh 3.6 g of hydrogenated soybean lecithin and 1.0 g of cholesterol as a film-forming substance, and 0.14 g of N-(β-D-glucopyranose) octanamide as a film-forming substance stabilizer, and dissolve the above mixture with 120 mL of ether; To which was added containing 0.135gC 20 h 18 N 6 Na 2 o 7 S 4 20mL of PBS buffer solution with a pH value of 6.0, ultrasonically make the mixed system into a homogeneous system; evaporate the organic solvent under reduced pressure until a gel is formed, add 10mL of PBS buffer solution with a pH value of 6.0 for hydration reaction, and the temperature is 30°C , the hydration time is 2h; then continue to evaporate under reduced pressure for 15 minutes; after ultrasonication, let it stand for 3h at a temperature of 4°C to obtain the above C 20 h 18 N 6 Na 2 o 7 S 4 Composition of pharmaceutical entities.

Embodiment 2

[0049] Weigh 3.6 g of hydrogenated soybean lecithin and 1.0 g of cholesterol as a film-forming substance, and 0.131 g of N-(β-D-glucopyranose) octanamide as a film-forming substance stabilizer, and dissolve the above mixture with 120 mL of ether; To which was added containing 0.135gC 20 h 18 N 6 Na 2 o 7 S 4 15mL of PBS buffer solution with a pH value of 5.5, ultrasonically make the mixed system into a homogeneous system; evaporate the organic solvent under reduced pressure until a gel is formed, add 5mL of PBS buffer solution with a pH value of 5.5 for hydration reaction, and the temperature is 35°C , the hydration time is 2h; then continue to evaporate under reduced pressure for 15 minutes; after ultrasonication, let it stand for 1h at a temperature of 4°C to obtain the above C 20 h 18 N 6 Na 2 o 7 S 4 Composition of pharmaceutical entities.

Embodiment 3

[0051] Weigh 3.6 g of hydrogenated soybean lecithin and 1.0 g of cholesterol as a film-forming substance, and 0.175 g of N-(β-D-glucopyranose) octanamide as a film-forming substance stabilizer, and dissolve the above mixture with 120 mL of ether; To which was added containing 0.135gC 20 h 18 N 6 Na 2 o 7 S 4 30mL of PBS buffer solution with a pH value of 6.5, ultrasonically make the mixed system into a homogeneous system; evaporate the organic solvent under reduced pressure until a gel is formed, add 10mL of PBS buffer solution with a pH value of 6.5 for hydration reaction, and the temperature is 25°C , the hydration time is 2h; then continue to evaporate under reduced pressure for 15 minutes; after ultrasonication, let it stand for 4h at a temperature of 4°C to obtain the above C 20 h 18 N 6 Na 2 o 7 S 4 Composition of pharmaceutical entities.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a C20H18N6Na2O7S4 drug entity composition and a preparation for children. Raw materials of the C20H18N6Na2O7S4 drug entity composition and the preparation for the children comprise hydrogenated soybean lecithin and cholesterin of a film forming substance and C20H18N6Na2O7S4, and the raw materials further comprise D-pyrane glucosamide serving as a film forming substance stabilizer.

Description

technical field [0001] The invention belongs to the field of medicine; relates to a C 20 h 18 N 6 Na 2 o 7 S 4 Pharmaceutical entity composition, especially a new type of C for children 20 h 18 N 6 Na 2 o 7 S 4 Pharmaceutical entity compositions and preparations. Background technique [0002] C 20 h 18 N 6 Na 2 o 7 S 4 The chemical name is: (6R, 7R)-7-[(2-amino-4-thiazolyl)(methoxyimino)acetamido]-3-[[(5-carboxymethyl-4-methyl-2 -thiazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt, molecular weight 628.6, belongs to β-endo Amide cephalosporins. This product is a third-generation broad-spectrum semi-synthetic cephalosporin antibiotic jointly developed by Hearst Company of Germany and Roussel Company of France. C 20 h 18 N 6 Na 2 o 7 S 4 Raw material and C for injection 20 h 18 N 6 Na 2 o 7 S 4 All have been included in the second part of the Chinese Pharmacopoeia 2010 edition and 2015 edition. This ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/546A61K47/26A61K47/24A61K47/28A61P31/04
CPCA61K31/546A61K47/24A61K47/26A61K47/28
Inventor 傅苗青赵叶青毕秀莲朱旭伟周白水
Owner 广东金城金素制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com